Marksans unit gets UK marketing authorization for key products

Marksans Pharma Limited's wholly-owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK MHRA for two of its products. The newly authorized products are Mefenamic Acid 250 mg Film-Coated Tablets and Mefenamic Acid 500 mg Film-Coated Tablets.

This authorization allows Relonchem Limited to market these pharmaceutical formulations in the UK, enhancing Marksans Pharma's global product portfolio. Marksans Pharma, headquartered in Mumbai, India, specializes in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets.

The company's manufacturing facilities in India, USA, and UK are approved by major regulatory agencies, including USFDA, UKMHRA, and Australian TGA. Marksans Pharma's product portfolio covers therapeutic segments such as CVS, CNS, anti-diabetic, pain management, gastroenterological, and anti-allergies.